John C Lipscomb
Overview
Explore the profile of John C Lipscomb including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
449
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pfohl M, Silvestri E, Lipscomb J, Snyder E, Willison S
J Toxicol Environ Health A
. 2022 May;
85(15):622-647.
PMID: 35499183
The unexpected release of chemicals into the environment requires estimation of human health risks, followed by risk management decisions. When environmental concentrations of toxicants are associated with adverse health risks,...
2.
Kenyon E, Eklund C, Pegram R, Lipscomb J
Toxicol In Vitro
. 2020 Nov;
75:105045.
PMID: 33160764
No abstract available.
3.
Kenyon E, Eklund C, Pegram R, Lipscomb J
Toxicol In Vitro
. 2020 Sep;
69:105002.
PMID: 32946980
Metabolic rate parameters estimation using in vitro data is necessary due to numbers of chemicals for which data are needed, trend towards minimizing laboratory animal use, and limited opportunity to...
4.
Lipscomb J
Toxicol Pathol
. 2019 Oct;
47(8):1027-1034.
PMID: 31581901
Chemical exposures are routine; some are controlled, some are not. Whether an exposure should be controlled depends on the acceptability of the consequences of controlling or not controlling the exposure....
5.
Kenyon E, Lipscomb J, Pegram R, George B, Hines R
Toxicol Sci
. 2018 Sep;
167(2):347-359.
PMID: 30252107
Biotransformation rates extrapolated from in vitro data are used increasingly in human physiologically based pharmacokinetic (PBPK) models. This practice requires use of scaling factors, including microsomal content (mg of microsomal...
6.
Juberg D, Knudsen T, Sander M, Beck N, Faustman E, Mendrick D, et al.
Toxicol Sci
. 2016 Oct;
155(1):22-31.
PMID: 27780885
Future Tox III, a Society of Toxicology Contemporary Concepts in Toxicology workshop, was held in November 2015. Building upon Future Tox I and II, Future Tox III was focused on...
7.
Kenyon E, Eklund C, Lipscomb J, Pegram R
Toxicol Mech Methods
. 2016 Sep;
26(8):620-626.
PMID: 27595344
A rate for hepatic metabolism (V) determined in vitro must be scaled for in vivo use in a physiologically based pharmacokinetic (PBPK) model. This requires the use of scaling factors...
8.
Meek M, Lipscomb J
Toxicology
. 2015 Jan;
332:112-23.
PMID: 25598226
Testing strategies are anticipated to increasingly rely on in vitro data as a basis to characterize early steps or key events in toxicity at relevant dose levels in human tissues....
9.
Bale A, Kenyon E, Flynn T, Lipscomb J, Mendrick D, Hartung T, et al.
ALTEX
. 2013 Nov;
31(1):79-90.
PMID: 24248035
A special session at the Toxicology and Risk Assessment Conference in Cincinnati, OH, USA in May, 2012 presented approaches expanding upon current uses of in vitro toxicity data for risk...
10.
Meek M, Barton H, Bessems J, Lipscomb J, Krishnan K
Regul Toxicol Pharmacol
. 2013 Mar;
66(1):116-29.
PMID: 23535119
The World Health Organization (WHO) International Programme on Chemical Safety (IPCS) Guidance on Characterization and Application of Physiologically Based Pharmacokinetic Models in Risk Assessment (IPCS, 2010) describes key principles for...